Haemonetics (HAE) Cash & Equivalents (2009 - 2026)

Haemonetics' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 19.99% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $245.4 million (down 19.99% YoY), while the FY2026 annual figure was $245.4 million, down 19.99% from the prior year.
• Cash & Equivalents was $245.4 million for Q1 2026 at Haemonetics, down from $363.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $363.4 million in Q4 2025 to a low of $178.8 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $274.4 million across 5 years, with a median of $285.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 37.15% in 2024, then jumped 71.57% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $224.0 million in 2022, then retreated by 13.4% to $194.0 million in 2023, then jumped by 65.4% to $320.8 million in 2024, then rose by 13.25% to $363.4 million in 2025, then tumbled by 32.45% to $245.4 million in 2026.
• The last three Cash & Equivalents figures came in at $245.4 million (Q1 2026), $363.4 million (Q4 2025), and $296.4 million (Q3 2025), per Business Quant data.